Insulin: Key Hormone for Metabolic Homeostasis
Insulin is an essential protein hormone in the human metabolic regulatory network. Synthesized and secreted by pancreatic β-cells, it serves as a core hub for maintaining blood glucose homeostasis and regulating energy metabolism. Since its first discovery in 1921, insulin has not only been a pivotal drug for diabetes treatment, but also one of the most classic biomarkers for metabolic disease research, drug development and preclinical evaluation.
Structurally, insulin consists of two peptide chains (Chain A and Chain B) linked by disulfide bonds. By binding to the insulin receptor (IR) on the surface of target cells, it activates downstream signaling pathways and precisely modulates glucose uptake, glycogen synthesis, lipid metabolism and protein synthesis. It plays an irreplaceable role in sustaining bodily energy balance and normal physiological functions.
Acting as the master regulator connecting blood glucose regulation and systemic metabolism, insulin participates in a wide range of physiological processes. It promotes glucose uptake and utilization in skeletal muscle and adipose tissue, and inhibits hepatic gluconeogenesis and glycogenolysis, thereby lowering blood glucose levels. Meanwhile, it facilitates lipogenesis and suppresses lipolysis to reduce the release of free fatty acids. It also accelerates protein synthesis, inhibits protein degradation, and regulates cell proliferation and differentiation.
Insufficient insulin secretion or impaired bioactivity directly leads to hyperglycemia and diabetes. Long-term insulin resistance can trigger multiple metabolic disorders such as obesity, metabolic syndrome and polycystic ovary syndrome (PCOS). Accordingly, dynamic changes in insulin levels are critical indicators for assessing pancreatic islet function, disease progression and therapeutic efficacy.
In disease research, insulin is not only a core indicator for diabetes studies, but also closely associated with the onset and progression of various illnesses. In the early stage of type 2 diabetes mellitus (T2DM), patients usually present compensatory hypersecretion of insulin accompanied by insulin resistance. As the disease progresses, pancreatic β-cell function declines gradually, and insufficient insulin secretion becomes the dominant feature.
In cases of obesity and metabolic syndrome, dysfunctional adipose tissue induces chronic inflammation, which further exacerbates insulin resistance and forms a vicious cycle of "obesity-insulin resistance-metabolic disorder". In addition, insulin regulates the proliferation and metabolic reprogramming of tumor cells and exerts important effects on the tumor microenvironment, making it a hot topic in interdisciplinary research linking oncology and metabolism.
In laboratory research, insulin concentrations in samples such as serum, plasma and cell culture supernatant are generally low. Its detection is vulnerable to interference from sample handling procedures and matrix components, which places high requirements on the sensitivity, specificity and reproducibility of detection methods.
Enzyme-Linked Immunosorbent Assay (ELISA) has become the gold standard for quantitative detection of insulin, thanks to its high sensitivity, simple operation and capacity for high-throughput testing. Our human insulin ELISA kit adopts a repeatedly validated high-specificity antibody pairing system, combined with optimized immune reaction and washing systems. It achieves detection sensitivity at the picogram (pg) level and possesses a broad linear detection range. The kit can stably capture trace insulin signals and effectively reduce matrix interference and background noise.
Featuring minimal inter-assay variation and excellent reproducibility, the product is equipped with a fully standardized operating procedure that requires no complex pre-experimental adjustment, making it compatible with routine laboratory conditions. It provides stable and reliable quantitative data for metabolic mechanism research, pharmacodynamic evaluation, disease model analysis and drug screening. It helps researchers accurately elucidate the pathogenesis of insulin-related diseases and accelerates the research and development of therapeutic strategies for metabolic disorders.
Structurally, insulin consists of two peptide chains (Chain A and Chain B) linked by disulfide bonds. By binding to the insulin receptor (IR) on the surface of target cells, it activates downstream signaling pathways and precisely modulates glucose uptake, glycogen synthesis, lipid metabolism and protein synthesis. It plays an irreplaceable role in sustaining bodily energy balance and normal physiological functions.
Acting as the master regulator connecting blood glucose regulation and systemic metabolism, insulin participates in a wide range of physiological processes. It promotes glucose uptake and utilization in skeletal muscle and adipose tissue, and inhibits hepatic gluconeogenesis and glycogenolysis, thereby lowering blood glucose levels. Meanwhile, it facilitates lipogenesis and suppresses lipolysis to reduce the release of free fatty acids. It also accelerates protein synthesis, inhibits protein degradation, and regulates cell proliferation and differentiation.
Insufficient insulin secretion or impaired bioactivity directly leads to hyperglycemia and diabetes. Long-term insulin resistance can trigger multiple metabolic disorders such as obesity, metabolic syndrome and polycystic ovary syndrome (PCOS). Accordingly, dynamic changes in insulin levels are critical indicators for assessing pancreatic islet function, disease progression and therapeutic efficacy.
In disease research, insulin is not only a core indicator for diabetes studies, but also closely associated with the onset and progression of various illnesses. In the early stage of type 2 diabetes mellitus (T2DM), patients usually present compensatory hypersecretion of insulin accompanied by insulin resistance. As the disease progresses, pancreatic β-cell function declines gradually, and insufficient insulin secretion becomes the dominant feature.
In cases of obesity and metabolic syndrome, dysfunctional adipose tissue induces chronic inflammation, which further exacerbates insulin resistance and forms a vicious cycle of "obesity-insulin resistance-metabolic disorder". In addition, insulin regulates the proliferation and metabolic reprogramming of tumor cells and exerts important effects on the tumor microenvironment, making it a hot topic in interdisciplinary research linking oncology and metabolism.
In laboratory research, insulin concentrations in samples such as serum, plasma and cell culture supernatant are generally low. Its detection is vulnerable to interference from sample handling procedures and matrix components, which places high requirements on the sensitivity, specificity and reproducibility of detection methods.
Enzyme-Linked Immunosorbent Assay (ELISA) has become the gold standard for quantitative detection of insulin, thanks to its high sensitivity, simple operation and capacity for high-throughput testing. Our human insulin ELISA kit adopts a repeatedly validated high-specificity antibody pairing system, combined with optimized immune reaction and washing systems. It achieves detection sensitivity at the picogram (pg) level and possesses a broad linear detection range. The kit can stably capture trace insulin signals and effectively reduce matrix interference and background noise.
Featuring minimal inter-assay variation and excellent reproducibility, the product is equipped with a fully standardized operating procedure that requires no complex pre-experimental adjustment, making it compatible with routine laboratory conditions. It provides stable and reliable quantitative data for metabolic mechanism research, pharmacodynamic evaluation, disease model analysis and drug screening. It helps researchers accurately elucidate the pathogenesis of insulin-related diseases and accelerates the research and development of therapeutic strategies for metabolic disorders.
